Remuneration Report Table 5: Executive KMP STI outcomes in FY26 The following table sets out STI outcomes for Executive KMP, after the Board exercised its discretion to reduce outcomes. As noted above, Mr Naylor did not participate in the FY26 STI plan. Executive Value of STI earned US$ STI earned as % of maximum opportunity19 STI earned as % of FR K Lim 20 $123,545 12% 25% A Schmeltz $0.00 0% 0% Former Executive P McKenzie $0.00 0% 0% J Linton $0.00 0% 0% 19. The STI earned is the maximum FY26 STI that will be paid to the Executive KMP. Any STI that was not earned is automatically forfeited. If none of the performance hurdles had been met, the minimum FY26 STI paid would have been zero. 20. In FY26, K Lim was an executive KMP for the period of 7 October 2025 to 30 June 2026. For transparency, the full year of STI payment for K Lim was $158,597. 6.2 LTI Outcomes As set out in Table 6 below, the LTI award that was performance tested at 30 June 2026 will lapse on 1 September 2026 with no vesting (i.e. 0% vesting outcome). In determining these outcomes, the Board made no adjustments in relation to one-off items. Table 6: LTI Awards tested as of 30 June 2026 Grant Date Security Tranche Weight Performance measure Performance period Performance level Performance outcome Vesting Outcome21 1 September 2023 PSU 1 70% ROIC 1 July 2023 – 30 June 2026 Threshold – 10.2% Target – 12.8% 4.1 % 0 % 1 September 2023 PSU 2 30% EPSg 1 July 2023 – 30 June 2026 Threshold – 15.6% Target – 17.3% (205) % 0 % 21. The remaining portion of each tranche has lapsed – there is no retest. For other on-foot LTI awards, it is the Board's intention to adjust out the impact of FY26 one-off items (such as the material impairments) so as not to disincentivise current Management moving forward. This will impact the 3-year average ROIC calculations used for the awards scheduled to vest on 1 September 2027 and 1 September 2028. 6.3 Executive KMP exit arrangements The following table sets out the treatment of Dr McKenzie, Ms Linton and Mr Schmeltz’s STI and LTI awards on-foot at the time of their retirement, and other entitlements as appropriate. All payments are consistent with contractual arrangements. Former Executive KMP Relevant Dates Remuneration Treatment on retirement P McKenzie – Stepped down as CEO & MD on 10 February 2026. – Provided transitionary support during notice period from 10 February to 10 August 2026. – Retired on 10 August 2026. – Eligible for full-year FY26 STI (with an outcome of zero) and will not be eligible for FY27 STI. – 2024 and 2025 LTI awards pro-rated and retained, subject to the original terms and conditions including satisfaction of the performance conditions at the test date. – Non-compete payments will be paid for the 12 months following cessation (subject to compliance with the statutory termination benefits cap). – Continuation of medical benefits for the 12 months following cessation. – Ongoing indemnification against any additional tax on CSL remuneration in any jurisdiction other than the US. J Linton – Stepped down as CFO on 6 October 2025. – Transitionary support during extended notice period from 7 October 2025 to 1 September 2026. – Will retire on 1 September 2026. – Eligible for a pro-rata FY26 STI (with an outcome of zero) and will not be eligible for FY27 STI. – 2024 and 2025 LTI awards pro-rated and retained, subject to the original terms and conditions including satisfaction of the performance conditions at the test date. A Schmeltz – Stepped down as a Chief Commercial Officer on 30 June 2026. – Transitionary support during notice period from 1 July 2026 to 3 December 2026. – Will retire on 3 December 2026. – Eligible for full-year FY26 STI (with an outcome of zero) and will not be eligible for FY27 STI. – 2024 and 2025 LTI awards pro-rated and retained, subject to the original terms and conditions including satisfaction of the performance conditions at the test date. Directors’ Report Remuneration Report 1474 Directors’ Report
RkJQdWJsaXNoZXIy MjE2NDg3